{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:21:18Z","timestamp":1771975278808,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.mayocp.2021.07.022","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T07:47:00Z","timestamp":1638863220000},"page":"507-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sex and Race Disparities in Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-0217","authenticated-orcid":false,"given":"Sri Harsha","family":"Patlolla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartzell V.","family":"Schaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick A.","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-7420","authenticated-orcid":false,"given":"Shannon M.","family":"Dunlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve R.","family":"Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocp.2021.07.022_bib1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2021.07.022_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2014.06.1178","article-title":"20 years of cardiac resynchronization therapy","volume":"64","author":"Leyva","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2021.07.022_bib3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: a systematic review","volume":"287","author":"Maron","year":"2002","journal-title":"JAMA"},{"issue":"9862","key":"10.1016\/j.mayocp.2021.07.022_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2021.07.022_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200002103420601","article-title":"Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"342","author":"Maron","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2021.07.022_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mayocp.2021.07.022_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCRESAHA.119.315159","article-title":"Paradigm of sudden death prevention in hypertrophic cardiomyopathy","volume":"125","author":"Maron","year":"2019","journal-title":"Circ Res"},{"issue":"24","key":"10.1016\/j.mayocp.2021.07.022_bib8","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIR.0b013e318223e230","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.mayocp.2021.07.022_bib9","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.mayocp.2021.07.022_bib10","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2021.07.022_bib11","doi-asserted-by":"crossref","first-page":"e005820","DOI":"10.1161\/CIRCEP.117.005820","article-title":"Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators","volume":"11","author":"Maron","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"13","key":"10.1016\/j.mayocp.2021.07.022_bib12","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jama.298.13.1525","article-title":"Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure","volume":"298","author":"Hernandez","year":"2007","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.mayocp.2021.07.022_bib13","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.298.13.1517","article-title":"Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death","volume":"298","author":"Curtis","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.mayocp.2021.07.022_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.111.066605","article-title":"Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure","volume":"125","author":"Al-Khatib","year":"2012","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.mayocp.2021.07.022_bib15","first-page":"1485","article-title":"Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator","volume":"38","author":"Chatterjee","year":"2017","journal-title":"Eur Heart J"},{"issue":"46","key":"10.1016\/j.mayocp.2021.07.022_bib16","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","article-title":"Women with hypertrophic cardiomyopathy have worse survival","volume":"38","author":"Geske","year":"2017","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.mayocp.2021.07.022_bib17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.117.032838","article-title":"Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy","volume":"137","author":"Wells","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2021.07.022_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/CIRCULATIONAHA.115.018830","article-title":"National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator","volume":"133","author":"Lindvall","year":"2016","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.mayocp.2021.07.022_bib19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/eurheartj\/ehx100","article-title":"Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013","volume":"38","author":"Hosseini","year":"2017","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.mayocp.2021.07.022_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"7","key":"10.1016\/j.mayocp.2021.07.022_bib22","doi-asserted-by":"crossref","first-page":"e003846","DOI":"10.1161\/CIRCOUTCOMES.117.003846","article-title":"With great power comes great responsibility: big data research from the National Inpatient Sample","volume":"10","author":"Khera","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1016\/j.mayocp.2021.07.022_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ahj.2013.06.009","article-title":"Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications","volume":"166","author":"Vriesendorp","year":"2013","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.mayocp.2021.07.022_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jce.13005","article-title":"Appropriate implantable defibrillator therapy in adults with hypertrophic cardiomyopathy","volume":"27","author":"Thavikulwat","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"25","key":"10.1016\/j.mayocp.2021.07.022_bib25","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1161\/01.CIR.0000150390.04704.B7","article-title":"Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator","volume":"110","author":"Moss","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2021.07.022_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamacardio.2019.0084","article-title":"Survival differences in women and men after septal myectomy for obstructive hypertrophic cardiomyopathy","volume":"4","author":"Meghji","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.07.022_bib27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","article-title":"Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy","volume":"46","author":"Olivotto","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.07.022_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.112.136085","article-title":"Risk stratification and outcome of patients with hypertrophic cardiomyopathy \u226560 years of age","volume":"127","author":"Maron","year":"2013","journal-title":"Circulation"},{"issue":"2 suppl 1","key":"10.1016\/j.mayocp.2021.07.022_bib29","first-page":"S4","article-title":"Cardiac resynchronization therapy in women versus men: observational comparative effectiveness study from the National Cardiovascular Data Registry","volume":"8","author":"Zusterzeel","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25","key":"10.1016\/j.mayocp.2021.07.022_bib30","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.jacc.2012.01.065","article-title":"Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study","volume":"59","author":"Hsu","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2021.07.022_bib31","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0735-1097(02)02976-5","article-title":"Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy","volume":"41","author":"Maron","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.mayocp.2021.07.022_bib32","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/heartjnl-2016-309843","article-title":"Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK","volume":"102","author":"Sheikh","year":"2016","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.mayocp.2021.07.022_bib33","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2016.03.017","article-title":"Comparison of clinical features in blacks versus whites with hypertrophic cardiomyopathy","volume":"117","author":"Sorensen","year":"2016","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.07.022_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCOUTCOMES.110.958264","article-title":"Regional variation in the use of implantable cardioverter-defibrillators for primary prevention","volume":"4","author":"Matlock","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.mayocp.2021.07.022_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardfail.2010.11.009","article-title":"Regional variations in physicians\u2019 attitudes and recommendations surrounding implantable cardioverter-defibrillators","volume":"17","author":"Matlock","year":"2011","journal-title":"J\u00a0Card Fail"},{"issue":"9","key":"10.1016\/j.mayocp.2021.07.022_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/hrt.2008.150656","article-title":"Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy","volume":"95","author":"Lin","year":"2009","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.mayocp.2021.07.022_bib37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCHEARTFAILURE.112.969626","article-title":"Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy","volume":"5","author":"Schinkel","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.mayocp.2021.07.022_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCULATIONAHA.106.637405","article-title":"Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure","volume":"114","author":"Stevenson","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2021.07.022_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/CIRCULATIONAHA.105.581884","article-title":"Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure","volume":"114","author":"Mark","year":"2006","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.mayocp.2021.07.022_bib40","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMsa051989","article-title":"Cost-effectiveness of implantable cardioverter-defibrillators","volume":"353","author":"Sanders","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2021.07.022_bib41","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/heartjnl-2015-308883","article-title":"Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure","volume":"102","author":"Mealing","year":"2016","journal-title":"Heart"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621006509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621006509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:37:17Z","timestamp":1758418637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619621006509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0025619621006509"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.07.022","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex and Race Disparities in Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}